Author Archives: Bruno Quinney

#CRISPR #Genetic editing

Study finds safer alternative to CRISPR

The most popular method of genetic editing, CRISPR, might not be the safest approach to treat incurable diseases, a new study has highlighted. The study, published by the University of California San Diego and Yale University, suggests small nuclear RNA base editing could be a safer approach… Read More

#News

Vials for medical research
#Cancer research #Great Ormond Street Hospital

Great Ormond Street Hospital Charity joins cancer research consortium

Great Ormond Street Hospital Charity (GOSH Charity) has joined Cancer Research Horizons and LifeArc as a core partner to help drive innovation in children’s and young people’s cancer treatment, drug discovery consortium C-Further has announced.  C-Further is an international consortium of drug discovery and development researchers, clinicians,… Read More

#Cancer Research #News

Urticaria or hives
#Antibody-based therapeutics #Atopic dermatitis

UCB publishes new data on clinical trials for galvokimig

Global biopharmaceutical company UCB has announced new 12-week efficacy and 18-week safety data from the Phase I/IIa first-in-patient trial for galvokimig, investigating treatment for atopic dermatitis (AD).  Galvokimig, a novel multi-specific antibody-based therapeutic, is currently under clinical investigation for adults living with moderate-to severe cases of AD. Read More

#News

Cancer research in laboratory
#Cancer research #Equity finance

Financing round paves way for AecorBio to investigate FT-002a

AecorBio has successfully completed an equity financing round of $1.5m (£1.1m), enabling the company to investigate its lead peptide candidate FT-002a to treat advanced prostate cancer.  AecorBio, formerly known as HBC Immunology Inc, will use the financing to enable an Investigational New Drug (IND) application with the US Food and… Read More

#Business & Investment #Cancer Research #News

Builders checking plans
#Cell line development

Abzena announces expansion of its cell line development platform

Abzena, the end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the expansion of its AbZelectPRO cell line development (CLD) platform.  The organisation announced the launch of two glutamine synthetase (“GS”) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins. The addition… Read More

#News

#GSK #Investment #Manufacturing

GSK to invest $30 billion in US over next five years

GSK will invest $30 billion (£22 billion) across the US over the next five years in research and development and supply chain infrastructure, the company has announced.  The investment includes a new $1.2 billion (£880 million) investment in advanced manufacturing facilities and AI and advanced digital technologies, delivering new next-generation… Read More

#Business & Investment #News

#AI #Drug development #Life sciences

State-of-the-art life sciences hub opened in London

Victoria House has been officially opened in London’s Bloomsbury Square as the capital’s state-of-the-art life sciences hub. The building was opened on Tuesday at a launch event which brought together leaders from science, academia, venture capital and the UK parliament. It is hoped Victoria House can help the UK achieve… Read More

#News

Neuronal inclusions in Huntington’s disease
#Biotech #Huntington's disease #Orphan drugs

EMA positive towards unique Huntington’s drug

The European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion for granting orphan drug designation (ODD) to the drug SOM3355 for the treatment of Huntington’s disease.  The decision made by the EMA’s Committee for Orphan Medical Product (COMP) recognises an ongoing… Read More

#News

#Pharmaceutical

Monte Rosa Therapeutics and Novartis collaborate on novel degraders 

Biotechnology company Monte Rosa Therapeutics has announced it will work with pharmaceutical company Novartis on the development of novel degraders for immune-mediated diseases.   As part of the collaboration, Monte Rosa and Novartis will look to accelerate the development of degraders for important immune-mediated diseases driven by highly credentialed and difficult-to-drug… Read More

#Business & Investment #News

#Cancer research #Drug discovery #Leukaemia

CAR-T therapy could be effective cancer treatment, study suggests

CAR-T therapy could be an effective treatment for leukaemia, preclinical data published by biotechnology company Gyala Therapeutics suggests.  The data emerged from a study highlighting the use of CAR-T therapy, GYA01, to treat acute myeloid leukaemia (AML) and T-cell acute lymphoblastic leukaemia (T-ALL). The study is the… Read More

#Cancer Research #News